Related Experiment Video
Updated: Dec 31, 2025
A Spheroid Killing Assay by CAR T Cells
Published on: December 12, 2018
Monitoring CAR-T-Cell Therapies Using the Nordic Healthcare Databases
Torbjörn Callréus1, Tarec Christoffer El-Galaly2, Mats Jerkeman3
1Department of Drug Design and Pharmacology, University of Copenhagen, Jagtvej 160, 2100, Copenhagen, Denmark. Torbjorn.Callreus@sund.ku.dk.
Abstract:
Following intense research efforts, modulation of the immune system has finally proved to be a viable approach for treating malignant disease. Recently, chimeric antigen receptor redirected T cells have achieved promising outcomes in patients with B-cell malignancies and they are currently also being investigated in other haematological malignancies, solid tumours and viral infections. Compared with traditional biopharmaceuticals, the properties of genetically modified chimeric antigen receptor redirected T-cell therapies differ in many aspects, thereby posing challenges in terms of post-authorisation data collection and data analysis. We believe that the network of population-based Nordic healthcare databases has some characteristics that can help provide important data on these new types of advanced products. In particular, the possibility of very long follow-up periods with a limited loss to follow-up is an important strength. Given the limited source population and slow access to data, a Nordic chimeric antigen receptor redirected T-cell monitoring project should be seen as complementary to other surveillance initiatives.
Insights
Chimeric antigen receptor (CAR) T-cell therapy shows promise for treating cancers. Nordic healthcare databases offer unique strengths for monitoring these advanced therapies due to long follow-up periods and robust data collection.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Immunotherapy, specifically chimeric antigen receptor (CAR) T-cell therapy, has emerged as a powerful strategy against malignant diseases.
- CAR T-cell therapies have demonstrated significant success in B-cell malignancies and are under investigation for other cancers and viral infections.
Purpose of the Study:
- To explore the utility of Nordic population-based healthcare databases for post-authorisation surveillance of CAR T-cell therapies.
- To identify the unique advantages of these databases for collecting and analyzing data on advanced therapeutic products.
Main Methods:
- Leveraging the characteristics of Nordic healthcare databases, including extensive patient registries and long-term follow-up capabilities.
- Proposing a Nordic CAR T-cell monitoring project to complement existing surveillance efforts.
Main Results:
- Nordic healthcare databases possess features conducive to monitoring advanced therapies like CAR T-cells.
- The potential for extended follow-up with minimal patient attrition is a key strength of these databases.
Conclusions:
- The Nordic healthcare database network is well-suited for generating crucial post-authorisation data on CAR T-cell therapies.
- A collaborative Nordic monitoring project can provide valuable insights, complementing other surveillance initiatives for these novel treatments.
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
